Tozasertib is primarily used in cancer research due to its ability to inhibit key kinases involved in cell division, particularly Aurora A and Aurora B kinases. By blocking these enzymes, it disrupts mitosis, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells. This makes it a valuable tool in studying potential treatments for various cancers, including leukemias and solid tumors. It has shown activity in preclinical models against cancer cells that are resistant to other therapies, highlighting its potential as a candidate for overcoming drug resistance. While not approved for clinical use, Tozasertib remains an important compound in oncology research and the development of targeted anti-cancer drugs.